1. Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico 
Kely Rely, Rosa María Galindo-Suárez, Pierre K. Alexandre, Erika Gabriela García-García, Emilio Muciño-Ortega, Guillermo Salinas- Escudero, Silvia Martínez-Valverde 
Value in Health Regional Issues 
Volume 1, Issue 2, Pages (December 2012)
DOI: /j.vhri
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1
Model structure.
Value in Health Regional Issues 2012 1, DOI: ( /j.vhri )
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
Scatter plot of 1000 incremental cost and incremental QALY for sirolimus versus tacrolimus in the prophylaxis of organ rejection in renal transplant recipients. QALY, quality-adjusted life-year.
Value in Health Regional Issues 2012 1, DOI: ( /j.vhri )
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

4. Fig. 3
Acceptability curve representing the probability that sirolimus (SIR) is cost-effective in comparison to tacrolimus (TAC) for different values of WTP for a QALY. QALY, quality-adjusted life-year; WTP, willingness to pay.
Value in Health Regional Issues 2012 1, DOI: ( /j.vhri )
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

5. Fig. 4
Tornado diagram of the univariate sensitivity analysis showing the impact of individual input parameters on the ICER per QALY. ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; SIR, sirolimus; TAC, tacrolimus.
Value in Health Regional Issues 2012 1, DOI: ( /j.vhri )
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

6. Fig. 5
Impact on (A) mortality, (B) the quality-adjusted life-year gained, and (C) dialysis risk from sirolimus or tacrolimus therapy. (D) Expected 20-year cumulative cost per patient.
Value in Health Regional Issues 2012 1, DOI: ( /j.vhri )
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions